Literature DB >> 24691607

Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis.

Jeffrey M Rohde1, Derek E Dimcheff1, Neil Blumberg2, Sanjay Saint3, Kenneth M Langa3, Latoya Kuhn4, Andrew Hickner5, Mary A M Rogers6.   

Abstract

IMPORTANCE: The association between red blood cell (RBC) transfusion strategies and health care-associated infection is not fully understood.
OBJECTIVE: To evaluate whether RBC transfusion thresholds are associated with the risk of infection and whether risk is independent of leukocyte reduction. DATA SOURCES: MEDLINE, EMBASE, Web of Science Core Collection, Cochrane Central Register of Controlled Trials, Cochrane Database of Sytematic Reviews, ClinicalTrials.gov, International Clinical Trials Registry, and the International Standard Randomized Controlled Trial Number register were searched through January 22, 2014. STUDY SELECTION: Randomized clinical trials with restrictive vs liberal RBC transfusion strategies. DATA EXTRACTION AND SYNTHESIS: Twenty-one randomized trials with 8735 patients met eligibility criteria, of which 18 trials (n = 7593 patients) contained sufficient information for meta-analyses. DerSimonian and Laird random-effects models were used to report pooled risk ratios. Absolute risks of infection were calculated using the profile likelihood random-effects method. MAIN OUTCOMES AND MEASURES: Incidence of health care-associated infection such as pneumonia, mediastinitis, wound infection, and sepsis.
RESULTS: The pooled risk of all serious infections was 11.8% (95% CI, 7.0%-16.7%) in the restrictive group and 16.9% (95% CI, 8.9%-25.4%) in the liberal group. The risk ratio (RR) for the association between transfusion strategies and serious infection was 0.82 (95% CI, 0.72-0.95) with little heterogeneity (I2 = 0%; τ2 <.0001). The number needed to treat (NNT) with restrictive strategies to prevent serious infection was 38 (95% CI, 24-122). The risk of infection remained reduced with a restrictive strategy, even with leukocyte reduction (RR, 0.80 [95% CI, 0.67-0.95]). For trials with a restrictive hemoglobin threshold of <7.0 g/dL, the RR was 0.82 (95% CI, 0.70-0.97) with NNT of 20 (95% CI, 12-133). With stratification by patient type, the RR was 0.70 (95% CI, 0.54-0.91) in patients undergoing orthopedic surgery and 0.51 (95% CI, 0.28-0.95) in patients presenting with sepsis. There were no significant differences in the incidence of infection by RBC threshold for patients with cardiac disease, the critically ill, those with acute upper gastrointestinal bleeding, or for infants with low birth weight. CONCLUSIONS AND RELEVANCE: Among hospitalized patients, a restrictive RBC transfusion strategy was associated with a reduced risk of health care-associated infection compared with a liberal transfusion strategy. Implementing restrictive strategies may have the potential to lower the incidence of health care-associated infection.

Entities:  

Mesh:

Year:  2014        PMID: 24691607      PMCID: PMC4289152          DOI: 10.1001/jama.2014.2726

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  37 in total

1.  Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America.

Authors:  John M Boyce; Didier Pittet
Journal:  MMWR Recomm Rep       Date:  2002-10-25

2.  A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.

Authors:  P C Hébert; G Wells; M A Blajchman; J Marshall; C Martin; G Pagliarello; M Tweeddale; I Schweitzer; E Yetisir
Journal:  N Engl J Med       Date:  1999-02-11       Impact factor: 91.245

3.  The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants.

Authors:  Haresh Kirpalani; Robin K Whyte; Chad Andersen; Elizabeth V Asztalos; Nancy Heddle; Morris A Blajchman; Abraham Peliowski; Angel Rios; Meena LaCorte; Robert Connelly; Keith Barrington; Robin S Roberts
Journal:  J Pediatr       Date:  2006-09       Impact factor: 4.406

4.  Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome.

Authors:  A W Bracey; R Radovancevic; S A Riggs; S Houston; H Cozart; W K Vaughn; B Radovancevic; H A McAllister; D A Cooley
Journal:  Transfusion       Date:  1999-10       Impact factor: 3.157

5.  Allogeneic blood transfusions explain increased mortality in women after coronary artery bypass graft surgery.

Authors:  Mary A M Rogers; Neil Blumberg; Sanjay K Saint; Catherine Kim; Brahmajee K Nallamothu; Kenneth M Langa
Journal:  Am Heart J       Date:  2006-12       Impact factor: 4.749

6.  Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis.

Authors:  Gary E Hill; William H Frawley; Karl E Griffith; John E Forestner; Joseph P Minei
Journal:  J Trauma       Date:  2003-05

7.  Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials.

Authors:  Dean Fergusson; Madhu Priya Khanna; Alan Tinmouth; Paul C Hébert
Journal:  Can J Anaesth       Date:  2004-05       Impact factor: 5.063

8.  A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group.

Authors:  E P Vichinsky; C M Haberkern; L Neumayr; A N Earles; D Black; M Koshy; C Pegelow; M Abboud; K Ohene-Frempong; R V Iyer
Journal:  N Engl J Med       Date:  1995-07-27       Impact factor: 91.245

9.  A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture.

Authors:  J L Carson; M L Terrin; F B Barton; R Aaron; A G Greenburg; D A Heck; J Magaziner; F E Merlino; G Bunce; B McClelland; A Duff; H Noveck
Journal:  Transfusion       Date:  1998-06       Impact factor: 3.157

10.  Silent myocardial ischaemia and haemoglobin concentration: a randomized controlled trial of transfusion strategy in lower limb arthroplasty.

Authors:  M Grover; S Talwalkar; A Casbard; H Boralessa; M Contreras; H Boralessa; S Brett; D R Goldhill; N Soni
Journal:  Vox Sang       Date:  2006-02       Impact factor: 2.144

View more
  135 in total

1.  Restrictive versus liberal red blood cell transfusion for cardiac surgery: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Babikir Kheiri; Ahmed Abdalla; Mohammed Osman; Tarek Haykal; Sai Chintalapati; James Cranford; Jason Sotzen; Meghan Gwinn; Sahar Ahmed; Mustafa Hassan; Ghassan Bachuwa; Deepak L Bhatt
Journal:  J Thromb Thrombolysis       Date:  2019-02       Impact factor: 2.300

2.  Can an Arthroplasty Registry Help Decrease Transfusions in Primary Total Joint Replacement? A Quality Initiative.

Authors:  David C Markel; Mark W Allen; Nicole M Zappa
Journal:  Clin Orthop Relat Res       Date:  2016-01       Impact factor: 4.176

3.  Safety of a Restrictive versus Liberal Approach to Red Blood Cell Transfusion on the Outcome of AKI in Patients Undergoing Cardiac Surgery: A Randomized Clinical Trial.

Authors:  Amit X Garg; Neal Badner; Sean M Bagshaw; Meaghan S Cuerden; Dean A Fergusson; Alexander J Gregory; Judith Hall; Gregory M T Hare; Boris Khanykin; Shay McGuinness; Chirag R Parikh; Pavel S Roshanov; Nadine Shehata; Jessica M Sontrop; Summer Syed; George I Tagarakis; Kevin E Thorpe; Subodh Verma; Ron Wald; Richard P Whitlock; C David Mazer
Journal:  J Am Soc Nephrol       Date:  2019-06-20       Impact factor: 10.121

4.  [Cost analysis of patient blood management].

Authors:  A G Kleinerüschkamp; K Zacharowski; C Ettwein; M M Müller; C Geisen; C F Weber; P Meybohm
Journal:  Anaesthesist       Date:  2016-05-09       Impact factor: 1.041

Review 5.  Pre-operative anaemia: prevalence, consequences and approaches to management.

Authors:  Manuel Muñoz; Susana Gómez-Ramírez; Arturo Campos; Joaquín Ruiz; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2015-06-16       Impact factor: 3.443

6.  Post-Acute Care Use and Hospital Readmission after Sepsis.

Authors:  Tiffanie K Jones; Barry D Fuchs; Dylan S Small; Scott D Halpern; Asaf Hanish; Craig A Umscheid; Charles A Baillie; Meeta Prasad Kerlin; David F Gaieski; Mark E Mikkelsen
Journal:  Ann Am Thorac Soc       Date:  2015-06

Review 7.  Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.

Authors:  Lise J Estcourt; Reem Malouf; Marialena Trivella; Dean A Fergusson; Sally Hopewell; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2017-01-27

8.  Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial.

Authors:  Jeffrey L Carson; Frederick Sieber; Donald Richard Cook; Donald R Hoover; Helaine Noveck; Bernard R Chaitman; Lee Fleisher; Lauren Beaupre; William Macaulay; George G Rhoads; Barbara Paris; Aleksandra Zagorin; David W Sanders; Khwaja J Zakriya; Jay Magaziner
Journal:  Lancet       Date:  2014-12-09       Impact factor: 79.321

Review 9.  Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy.

Authors:  Anders Perner; Anthony C Gordon; Daniel De Backer; George Dimopoulos; James A Russell; Jeffrey Lipman; Jens-Ulrik Jensen; John Myburgh; Mervyn Singer; Rinaldo Bellomo; Timothy Walsh
Journal:  Intensive Care Med       Date:  2016-10-01       Impact factor: 17.440

10.  Red blood cell transfusion triggers in acute leukemia: a randomized pilot study.

Authors:  Amy E DeZern; Katherine Williams; Marianna Zahurak; Wesley Hand; R Scott Stephens; Karen E King; Steven M Frank; Paul M Ness
Journal:  Transfusion       Date:  2016-05-20       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.